EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory Diseases

Michelle W Cheung iD, Roya M Dayam, Janna R Shapiro iD, Jaclyn C Law, Gary Y C Chao iD, Daniel Pereira, Rogier L Goetgebuer iD, David Croitoru, Joanne M Stempak iD, Lily Acheampong, Saima Rizwan, Jenny D Lee iD und 14 weitere

The Journal of Immunology · 2023

DOI: 10.4049/jimmunol.2300190 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Immunology, 2023. Verfasst von Michelle W Cheung und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: COVID-19, Vaccines, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR, Gouvernement du Canada | Canadian Institutes of Health Research, Public Health Agency of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Previous studies have reported impaired humoral responses after SARS-CoV-2 mRNA vaccination in patients with immune-mediated inflammatory diseases (IMIDs), particularly those treated with anti-TNF biologics. We previously reported that IMID patients diagnosed with inflammatory bowel disease, psoriasis, psoriatic arthritis, ankylosing spondylitis, or rheumatoid arthritis exhibited greater waning of Ab and T cell responses than healthy control subjects after SARS-CoV-2 vaccine dose 2. Fewer data are available on the effects of third and fourth doses. This observational cohort study collected plasma and PBMCs from healthy control subjects and untreated or treated patients with IMIDs prevaccination and after one to four doses of SARS-CoV-2 mRNA vaccine (BNT162b2 or mRNA-1273). SARS-CoV-2–specific Ab levels, neutralization, and T cell cytokine release were measured against wild-type and Omicron BA.1 and BA.5 variants of concern. Third vaccine doses substantially restored and prolonged Ab and T cell responses in patients with IMIDs and broadened responses against variants of concern. Fourth-dose effects were subtle but also prolonged Ab responses. However, patients with IMIDs treated with anti-TNF, especially patients with inflammatory bowel disease, exhibited lower Ab responses even after the fourth dose. Although T cell IFN-γ responses were maximal after one dose, IL-2 and IL-4 production increased with successive doses, and early production of these cytokines was predictive of neutralization responses at 3–4 mo postvaccination. Our study demonstrates that third and fourth doses of the SARS-CoV-2 mRNA vaccines sustain and broaden immune responses to SARS-CoV-2, supporting the recommendation for three- and four-dose vaccination regimens in patients with IMIDs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19VaccinesInflammatory Bowel DiseasesHumansAdultCOVID-19 VaccinesSARS-CoV-2BNT162 VaccineImmunomodulating AgentsTumor Necrosis Factor InhibitorsVaccinationCytokinesAntibodies, Viral

Substanzen

COVID-19 VaccinesBNT162 VaccineImmunomodulating AgentsTumor Necrosis Factor InhibitorsVaccinesCytokinesAntibodies, Viral

Autor:innen und Institutionen

  • Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, Ontario, Canada.
  • Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada.
  • Zane Cohen Centre for Digestive Diseases, Division of Gastroenterology, Mount Sinai Hospital, Sinai Health, Toronto, Ontario, Canada.
  • Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada.

ORCID-Profile: Michelle W Cheung, Janna R Shapiro, Gary Y C Chao, Rogier L Goetgebuer, Joanne M Stempak, Jenny D Lee, Victoria E Rodriguez-Castellanos, Madeline Kern-Smith, Nigil Haroon, Robert D Inman, Vincent Piguet, Tania H Watts, Anne-Claude Gingras

Förderung

  • CIHR
  • Gouvernement du Canada | Canadian Institutes of Health Research
  • Public Health Agency of Canada

Zitieren

APA

Cheung, M. W., Dayam, R. M., Shapiro, J. R., Law, J. C., Chao, G. Y. C., Pereira, D., Goetgebuer, R. L., Croitoru, D., Stempak, J. M., Acheampong, L., Rizwan, S., Lee, J. D., Jacob, L., Ganatra, D., Law, R., Rodriguez-Castellanos, V. E., Kern-Smith, M., Delgado-Brand, M., Mailhot, G., …, & Gingras, A. C. (2023). Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory Diseases. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2300190

Vancouver

Cheung MW, Dayam RM, Shapiro JR, Law JC, Chao GYC, Pereira D, et al. Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory Diseases. The Journal of Immunology. 2023. doi:10.4049/jimmunol.2300190

BibTeX
@article{Cheung2023,
  author = {Cheung, Michelle W and Dayam, Roya M and Shapiro, Janna R and Law, Jaclyn C and Chao, Gary Y C and Pereira, Daniel and Goetgebuer, Rogier L and Croitoru, David and Stempak, Joanne M and Acheampong, Lily and Rizwan, Saima and Lee, Jenny D and Jacob, Liz and Ganatra, Darshini and Law, Ryan and Rodriguez-Castellanos, Victoria E and Kern-Smith, Madeline and Delgado-Brand, Melanie and Mailhot, Genevieve and Haroon, Nigil and Inman, Robert D and Piguet, Vincent and Chandran, Vinod and Silverberg, Mark S and Watts, Tania H and Gingras, Anne-Claude},
  title = {Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory Diseases},
  journal = {The Journal of Immunology},
  year = {2023},
  doi = {10.4049/jimmunol.2300190}
}
Kostenlos starten →